Skip to main content
ARS Home » Research » Publications at this Location » Publication #214544

Title: US Veterinary Immune Reagent Network: Prioritization & Progress

item Lunney, Joan
item BLACK, S
item Boyd, Patricia
item Lillehoj, Hyun
item MILLER, N
item WILSON, M
item WAGNER, H

Submitted to: International Symposium on Animal Genomics for Animal Health
Publication Type: Abstract Only
Publication Acceptance Date: 8/22/2007
Publication Date: 10/22/2007
Citation: Lunney, J.K., Baldwin, C., Black, S.J., Boyd, P., Lillehoj, H.S., Labresh, J., Horohov, D., Miller, N., Bengten, E., Chinchar, G., Wilson, M., Wagner, H.October 2007. Us veterinary immune reagent network: prioritization & progress. Proceedings Intl Symposium on Animal Genomics for Animal Health, Paris, France.P. 33.

Interpretive Summary:

Technical Abstract: The US Veterinary Immune Reagent Network represents a broad community plan to begin to systematically address the immunological reagent gap for the US veterinary immunology research community including for the following groups: ruminants (concentrating on cattle), swine, poultry (primarily chickens), horses and aquaculture species (concentrating on channel catfish and trout) with a goal of developing 20 reagents per species group. Advances in genomics, including full genome sequences for chicken, cattle and horses, have provided improved data for gene and protein expression. The genome and EST data provides an excellent basis on which to accurately predict protein sequences for expression work that is the basis for production of needed immunological reagents including recombinant cytokines and chemokines and immune cell surface markers. Monoclonal antibodies (mAb) will be generated to identify the major leukocyte subsets (T and B lymphocytes, NK cells, macrophages, dendritic cells, neutrophils), react with cytokines/chemokines and their receptors, and target other important receptors that modulate immune function such as toll-like receptors are used to evaluate changes during disease including the causes of immune-pathology. These reagents will help scientists evaluate host responses to vaccination and provide the means to manipulate or modulate immune responses either to enhance protective immune responses to infections or to reduce immune-system-mediated pathology. The project directors are coordinating their efforts with other international groups and are continually revising the prioritization list and seeking input from scientists working with these species. A list of currently targeted reagents and progress regarding these will be presented.